MedTrace Logo

Epidemiology Study of Malaria Transmission Intensity in Sub-Saharan Africa

NCT02251704 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 54115

Last updated 2025-07-24

Study results available
· View outcomes & findings →

Summary

This epidemiology study was conducted in parallel with the EPI-MAL-002 (NCT02374450) and EPI-MAL-003 (NCT03855995) studies, enrolling participants from the same health and demographic surveillance system (HDSS) (or equivalent system) populations. The co-primary objectives were to produce longitudinal estimates of parasite prevalence in humans and to record the usage of malaria control measures in areas where the EPI-MAL-002 and EPI-MAL-003 studies were conducted.

Conditions

Interventions

DIAGNOSTIC_TEST

Assessment of body temperature

Axillary body temperature of all participants recorded by a digital thermometer at the time of survey.

PROCEDURE

Blood sampling

Capillary blood samples collected by finger/heel prick for determination of parasite prevalence at the time of survey.

Sponsors & Collaborators

  • The PATH Malaria Vaccine Initiative (MVI)

    collaborator OTHER

  • GlaxoSmithKline

    lead INDUSTRY

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Study Design

Allocation
NON_RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
6 Months
Max Age
9 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-10-22
Primary Completion
2024-07-06
Completion
2024-07-06

Countries

  • Burkina Faso
  • Ghana
  • Kenya
  • Malawi
  • Senegal
  • Tanzania

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02251704 on ClinicalTrials.gov